2024-2036 年全球市场规模、预测和趋势亮点
The oncolytic virotherapy market size was valued at USD 20.10 million in 2023 and is expected to reach USD 334 million by the end of 2036, growing at a CAGR of approximately 26.7% during the forecast period (i.e. 2024-2036). In 2024, the oncolytic virotherapy industry size is expected to be USD 22.86 million. The reason behind the growth is the increasing incidence of cancer across the globe, which has led to a rapid increase in clinical trials and approvals of new virotherapy for cancer treatment. Clinical trials are being conducted to determine the effectiveness of oncolytic viruses as they are effective in treating specific types of cancer.
In addition, oncolytic viruses (OVs) are an emerging cancer therapy that uses modified viruses to attack and destroy tumor cells and are being used to treat cancer, particularly advanced metastatic melanoma. Cancer is the leading cause of death worldwide, with approximately 10 million deaths in 2020, according to the World Health Organization (WHO).
It is believed that the continuous advancement of viral engineering will drive the market growth. Viral vector production must develop rapidly, therefore, companies are testing many technological innovations to handle various aspects of viral vector gene therapy . With the advancement of genetic engineering technology, the ability of oncolytic viruses has been enhanced and can be used to create new anti-cancer technologies. It has become possible to develop tumor-selective oncolytic viruses that are effective against a variety of malignancies.
溶瘤病毒治疗领域：增长动力与挑战
Growth drivers
- Growing Demand for Personalized Therapies - Multiple scientific advances and a growing number of different pharmaceutical companies have driven the rise of personalized medicine. With personalized medicine, oncologists can tailor oncolytic viruses to target specific genetic variants, increasing the chances of treatment success.
More than 38% of all new drugs approved by the U.S. Food and Drug Administration (FDA) in 2020 were personalized medicine treatments. - Growing geriatric population - The elderly population is more susceptible to cancer and the cellular repair mechanisms of people become less effective with age, which is expected to drive the demand for oncolytic virotherapy as elderly patients with cancer seek better treatment options.
The population above 65 years is growing at an increasing rate globally and now exceeds 610 million people above 65 years of age.
challenge
- Side Effects of Treatment – Oncolytic viruses occasionally contaminate healthy cells and stimulate overall immune activity, they may also spread potential infection risks. Common side effects are chills, fatigue, flu-like symptoms, pain at the injection site, nausea, and fever, which can negatively impact the market growth.
- Limited access to healthcare in low- and middle-income countries
- Lack of specialized personnel to perform the treatment – Due to the difficulty of performing intratumoral injections, ordinary nurses are unable to perform these injections.
溶瘤病毒治疗细分
Therapy type (HSV-based, adenovirus-based, reovirus-based, poxvirus-based, NDV-based)
The HSV-based oncolytic virotherapy market is expected to gain a healthy revenue share of approximately 30% in the coming years owing to the large number of ongoing clinical trials related to the HSV virus. For instance, there are two existing variants of HSV: HSV type 1 (HSV-1) and HSV type 2 (HSV-2). Of the two existing variants, HSV-1 has been extensively studied in cancer oncolytic virotherapy. Approximately 58% of the U.S. population and approximately 67% of the global population have evidence of exposure to HSV-1 at some point in their lifetime. Furthermore, genome manipulation, cytotoxicity, pathogenicity, and availability of antiviral drugs have led to a growing demand for oncolytic HSV-1, which is widely used to treat melanoma.
End users (hospitals, specialist clinics, cancer research institutions)
Hospitals’ share in the oncolytic virus therapy market will grow significantly in the near future as most patients choose to go to these institutions for treatment. The survival rate and chances of successful treatment of patients with diseases such as cancer increase significantly when they receive early diagnosis in hospitals. Hospitals have round-the-clock medical professionals including oncologists and other specialists to formulate treatment plans for cancer patients.
Our in-depth analysis of the global market includes the following sections:
|
Types of treatment |
|
|
Virus Type |
|
|
Indications |
|
|
Demographics |
|
|
End User |
|
想根据您的需求定制此研究报告吗？我们的研究团队将涵盖您需要的信息，帮助您做出有效的商业决策。
定制此报告溶瘤病毒治疗行业-区域概要
North American Market Forecast
North America is expected to hold the largest share of the oncolytic virotherapy market at about 39% by the end of 2036, driven by growing clinical activities. This has led to the development of oncolytic viruses in the region that target serious diseases such as cancer, which are modifications of existing viruses. Hence, the demand for oncolytic virotherapy in the region is likely to increase as new modifications will offer more benefits and more patients will be eligible for treatment.
In terms of the number of clinical trial sites, Canada is followed by the United States, accounting for more than 3% of the total number of clinical trials worldwide.
European Market Statistics
The European oncolytic virotherapy market is expected to rank second during the forecast period, driven by the increase in the number of oncolytic virotherapy drug approvals. This has led to the development of new oncolytic viruses in the region, which are modifications of existing viruses for the treatment of serious diseases, including cancer. Therefore, the demand for oncolytic virotherapy in the region is likely to increase as new modifications will offer more benefits and more patients will be eligible for treatment.
溶瘤病毒治疗领域占据主导地位的公司
- Amgen
- Company Profile
- Business Strategy
- Main Products
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Developments
- Regional influence
- SWOT Analysis
- Shanghai Sanwei Biotechnology Co., Ltd.
- Oncolys BioPharma
- TILT Biotherapeutics Ltd.
- Ancorus
- TAKARA BIO CO., LTD.
- Villyard
- GMO companies
- Rocon Pharmaceuticals
- Pfizer
- Rigwell Group
- Xibaino Gene Technology Co., Ltd.
- Oncolytic Biotechnology
- Daiichi Sankyo
- Yoshisho Pharmaceutical Co., Ltd.
- Boehringer Ingelheim
In the News
- Daiichi Sankyo announced that its oncolytic virus G47 (trade name: DELYTACT) has been approved. The approval was mainly based on the results of the Japanese Ph2 study (investigator-led study) conducted in patients with residual or recurrent glioblastoma, led by Dr. Todo of the Institute of Medical Science, University of Tokyo.
- TILT Biotherapeutics Ltd. and Biotheus Inc. will collaborate to promote the global development and marketing of the cancer treatment product TILT-123 and make it available to Chinese cancer patients. In addition, the agreement involves an upfront payment and payments at specific stages during clinical research, and is eligible to receive significant royalties in future sales payments.
作者致谢: Radhika Pawar
- Report ID: 2988
- Published Date: Jun 07, 2024
- Report Format: PDF, PPT
